“Working” needs a definition

A medication can change a hormone measurement without changing the symptom that led someone to seek care. It can also coincide with an improvement that has another explanation. These are different possibilities, and a timeline cannot distinguish them unless the outcome is clear.

Before treatment, ask whether the purpose is to address a diagnosed condition, investigate a symptom, or pursue an elective wellness goal. Then ask how the clinician will judge benefit. “Your levels should improve” is incomplete if the reason for seeking care was poor sleep or limited physical function.

The same principle applies to a lack of response. An unchanged subjective feeling does not tell you to raise a dose, and an increased lab marker does not require you to accept an ineffective treatment indefinitely.

Study dates are not milestones

Research exampleWhat the timing tells usWhat it does not tell us
Six-week GHRH(1–29) studyResearchers compared measurements before and after that treatment periodThat visible muscle or fat changes should appear at week six
Six-month sermorelin cognition trialCognitive testing evaluated that study’s treatment intervalThat every adult should feel sharper by a particular month
Early hormone-response reportsA biological signal can be measured during a studyThat a meaningful clinical benefit has begun

There is a further naming problem: the 1997 Khorram paper tested a modified GHRH analog. Even a precisely reported timing result from that paper should not be presented as an established sermorelin milestone.

Why month-by-month promises are misleading

A schedule such as “sleep first, fat loss next, muscle later” implies that researchers have measured a predictable sequence. The evidence reviewed for these articles does not establish that sequence for sermorelin.

To validate it, a study would need repeated measurements of each outcome, an appropriate comparison group, and enough participants to describe variation reliably. It would also need to report how many people never experienced the advertised benefit. A list of selected testimonials cannot do that.

A fixed timeline can also create a poor decision rule: every disappointing month becomes a reason to purchase the next one. The relevant question is whether there is a justified treatment plan with a review date, not whether a marketing calendar says a result is still coming.

Build a useful record before the first review

Choose a small number of meaningful measures with the clinician. For sleep, a diary can capture nights and daytime function. For a physical limitation, a consistent task may be more useful than an occasional mirror check. For a diagnosed hormone disorder, laboratory interpretation belongs within the relevant medical evaluation.

Record other changes that could affect the result: new medications, a different work schedule, a new training plan, or a change in diet. This does not turn personal tracking into a clinical trial, but it makes the follow-up conversation more honest.

Keep measurements comparable. Changing the question at every appointment—from sleep to weight to a lab value—makes it hard to know whether treatment met the original goal.

Agree on a review plan, not an internet deadline

The timing of clinical follow-up should be individualized. Ask when the prescriber plans to reassess, which information is needed, and how to contact the practice between appointments. There is no universal monitoring schedule established by the studies discussed here for every compounded product or wellness use.

Discuss what happens if there is no meaningful improvement, if a new symptom appears, or if the burden and cost outweigh a modest benefit. These are ordinary treatment decisions, not evidence that you failed to be patient enough.

Practical details matter too. Confirm refill and cancellation terms so the financial schedule does not quietly become the medical schedule. A shipment interval is not evidence about how long treatment should continue.

Questions that lead to a clearer answer

  • What outcome should this prescription improve for me?
  • What evidence supports expecting that outcome at all?
  • When will we review benefit, tolerability, and whether to continue?
  • How will we distinguish a lab response from a benefit I can use?
  • What should prompt earlier contact?

If you are already taking sermorelin, follow your own clinician’s instructions and bring uncertainty to that clinician rather than changing the regimen yourself. For a closer look at two common promised outcomes, read our analyses of sleep and weight loss.

Sources & further reading

Sources reviewed October 2026. Provider prices and terms may change.

  1. Vittone et al. (1997): six-week GHRH(1–29) study in 11 older men
  2. Vitiello et al. (2006): randomized sermorelin cognition trial, full paper
  3. Khorram et al. (1997): study of modified [Nle27] GHRH, not unmodified sermorelin
  4. NHLBI: evaluation of insomnia and sleep diaries
  5. FDA: compounding questions and answers